Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GLNCY Glencore	$7.32 +2.7%	$6.96	$5.74 ▼ $12.53	$44.02B	0.94	1.18 million shs	992,012 shs
GVDNY Givaudan	$99.69 +1.7%	$92.13	$81.37 ▼ $110.32	$46.02B	0.78	25,354 shs	8,589 shs
HOCPY HOYA	$127.04 +3.9%	$115.43	$97.49 ▼ $148.27	$43.94B	0.93	37,943 shs	12,218 shs
RCDTF Recordati Industria Chimica e Farmaceutica	$56.04	$54.10	$49.00 ▼ $56.04	$11.56B	0.26	863 shs	N/A

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GLNCY Glencore	+2.81%	+3.83%	+3.98%	-8.73%	-40.10%
GVDNY Givaudan	+1.69%	+1.77%	+9.63%	+14.45%	+9.39%
HOCPY HOYA	+3.91%	+3.41%	+12.19%	+8.46%	+8.22%
RCDTF Recordati Industria Chimica e Farmaceutica	0.00%	0.00%	+14.37%	+0.91%	+8.61%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GLNCY Glencore	2.4031 of 5 stars	0.0	5.0	1.7	0.0	2.6	0.0	1.9
GVDNY Givaudan	0.5941 of 5 stars	0.0	5.0	0.8	0.0	0.0	0.0	0.6
HOCPY HOYA	1.3453 of 5 stars	0.0	3.0	1.7	0.0	1.8	0.0	1.9
RCDTF Recordati Industria Chimica e Farmaceutica	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GLNCY Glencore	4.00	Strong Buy	N/A	N/A
GVDNY Givaudan	2.33	Hold	N/A	N/A
HOCPY HOYA	0.00	N/A	N/A	N/A
RCDTF Recordati Industria Chimica e Farmaceutica	1.50	Reduce	N/A	N/A

Current Analyst Ratings Breakdown

Latest RCDTF, GVDNY, GLNCY, and HOCPY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
3/11/2025	GLNCY Glencore	Berenberg Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GLNCY Glencore	$230.94B	0.19	$1.67 per share	4.38	$6.27 per share	1.17
GVDNY Givaudan	$8.42B	5.47	$3.47 per share	28.77	$9.65 per share	10.33
HOCPY HOYA	$5.49B	8.00	$4.66 per share	27.24	$17.09 per share	7.43
RCDTF Recordati Industria Chimica e Farmaceutica	$2.25B	5.13	$3.09 per share	18.15	N/A	∞

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GLNCY Glencore	$4.28B	N/A	0.00	8.13	6.38	N/A	N/A	N/A	8/6/2025 (Estimated)
GVDNY Givaudan	$1.24B	N/A	0.00	33.34	4.33	N/A	N/A	N/A	7/22/2025 (Estimated)
HOCPY HOYA	$1.26B	$3.81	32.33	31.14	2.38	24.17%	21.34%	16.92%	8/7/2025 (Estimated)
RCDTF Recordati Industria Chimica e Farmaceutica	$421.25M	$2.00	28.02	∞	N/A	17.41%	30.78%	12.65%	7/29/2025 (Estimated)

Latest RCDTF, GVDNY, GLNCY, and HOCPY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/1/2025	Q4 2025	HOCPY HOYA	$0.99	$0.98	-$0.01	$0.98	$1.50 billion	$1.52 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GLNCY Glencore	$0.17	2.32%	N/A	N/A	N/A
GVDNY Givaudan	$0.95	0.95%	N/A	N/A	N/A
HOCPY HOYA	$0.59	0.46%	N/A	15.49%	N/A
RCDTF Recordati Industria Chimica e Farmaceutica	N/A	N/A	N/A	N/A	N/A

Latest RCDTF, GVDNY, GLNCY, and HOCPY Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/29/2025	GLNCY Glencore		$0.0850	2.75%	5/2/2025	5/5/2025	6/18/2025
3/3/2025	GVDNY Givaudan		$1.5503		3/25/2025	3/25/2025	4/9/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GLNCY Glencore	0.69	1.30	0.67
GVDNY Givaudan	0.99	1.43	0.94
HOCPY HOYA	0.02	5.04	4.35
RCDTF Recordati Industria Chimica e Farmaceutica	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GLNCY Glencore	0.06%
GVDNY Givaudan	0.01%
HOCPY HOYA	0.12%
RCDTF Recordati Industria Chimica e Farmaceutica	N/A

Insider Ownership

Company	Insider Ownership
GLNCY Glencore	N/A
GVDNY Givaudan	N/A
HOCPY HOYA	N/A
RCDTF Recordati Industria Chimica e Farmaceutica	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GLNCY Glencore	140,000	6.01 billion	N/A	Not Optionable
GVDNY Givaudan	16,260	461.68 million	N/A	Not Optionable
HOCPY HOYA	36,571	345.86 million	N/A	Not Optionable
RCDTF Recordati Industria Chimica e Farmaceutica	4,455	206.30 million	N/A	Not Optionable

RCDTF, GVDNY, GLNCY, and HOCPY Headlines

Recent News About These Companies

Drug maker Recordati's Q1 revenue rises 11.9%, confirms 2025 guidance

May 9, 2025 | msn.com

Recordati, ricavi ed EBITDA in crescita a doppia cifra nel primo trimestre

May 8, 2025 | teleborsa.it

Recordati stock rises following 1Q earnings beat

May 8, 2025 | investing.com

Recordati, la cassa balza a 158 milioni e il debito cala a 2 miliardi

May 8, 2025 | msn.com

Short Interest in Recordati Industria Chimica e Farmaceutica S.p.A. (OTCMKTS:RCDTF) Increases By 22.9%

May 5, 2025 | marketbeat.com

Campari e Recordati si Staccano dal FTSE MIB

May 3, 2025 | fxempire.it

Previsioni azioni industriali Italia: Buzzi, Recordati, STMicroelectronics

April 30, 2025 | fxempire.it

Italy’s Recordati Sees Tariff Volatility Fueling Dealmaking

April 30, 2025 | livemint.com

Recordati, al via domani un programma di acquisto di azioni proprie

April 29, 2025 | teleborsa.it

Recordati, ok da soci a bilancio e dividendo di 1,27 euro. Rinnovato CdA

April 29, 2025 | teleborsa.it

Recordati announces new three-year plan

April 29, 2025 | thepharmaletter.com

Recordati: in nuovo Piano ricavi 3-3,2mld e utile 770-820mln al 2027 (RCO)

April 29, 2025 | ilsole24ore.com

Recordati, CdA approva piano triennale. Utile fino a 820 milioni di euro

April 29, 2025 | finanza.repubblica.it

Azioni Recordati e nuovo piano industriale: cosa fare in borsa?

April 29, 2025 | borsainside.com

Recordati, i target finanziari al 2027

April 29, 2025 | soldionline.it

Recordati, ok dei soci al bilancio 2024 e al dividendo (staccato il 19 maggio)

April 29, 2025 | soldionline.it

Recordati Industria Chimica e Farmaceutica SPA (0KBS) Receives a Hold from RBC Capital

April 26, 2025 | markets.businessinsider.com

Recordati, la Fda amplia l’uso del farmaco Isturisa. Ma il titolo cade in borsa, ecco perché

April 18, 2025 | msn.com

Recordati, FDA approva estensione del farmaco Isturisa per trattamento ipercortisolemia

April 17, 2025 | finanza.repubblica.it

3 European Stocks Estimated To Be Trading At Discounts Of Up To 40.1%

April 17, 2025 | finance.yahoo.com

Recordati, la FDA approva la registrazione integrativa di un farmaco

April 16, 2025 | soldionline.it

New MarketBeat Followers Over Time

Media Sentiment Over Time

RCDTF, GVDNY, GLNCY, and HOCPY Company Descriptions

Glencore OTCMKTS:GLNCY

$7.32 +0.19 (+2.66%)

As of 05/23/2025 03:59 PM Eastern

Glencore plc engages in the production, refinement, processing, storage, transport, and marketing of metals and minerals, and energy products in the Americas, Europe, Asia, Africa, and Oceania. It operates through two segments: Marketing Activities and Industrial Activities. The company engages in production and marketing copper, cobalt, lead, nickel, zinc, chrome ore, ferrochrome, vanadium, aluminum, alumina, and iron ore; and coal, crude oil, refined products, and natural gas, as well as oil exploration/production and refining/distribution. It also operates marketing and distribution of physical commodities sourced from third party producers and company's production to industrial consumers, including the battery, electronic, construction, automotive, steel, energy, and oil industries. In addition, the company provides financing, logistics, and other services to producers and consumers of commodities. Glencore plc was founded in 1974 and is headquartered in Baar, Switzerland.

Givaudan OTCMKTS:GVDNY

$99.69 +1.66 (+1.69%)

As of 05/23/2025 03:59 PM Eastern

Givaudan SA manufactures, supplies, and sells fragrance, beauty, taste, and wellbeing products to the consumer goods industry. The company operates through divisions, Fragrance & Beauty, and Taste & Wellbeing. The Fragrance & Beauty division offers fine fragrances; consumer products, such as personal, home, fabric, and oral care; fragrance ingredients; and active beauty products. The Taste & Wellbeing division provides beverages, such as fizzy drinks, bottled waters, ready-to-drink juices, alcoholic beverages, and others; dairy and cheese products, including dairy drinks, yoghurt, ice cream, chilled desserts, cream cheese, and spreads; snacks; givaudan flavour ingredients; savory, and supplements and nutraceutical products; and biscuits, crackers, and cereals, as well as confectionery products, such as chewing gums, chocolates, and sweets. It operates in Switzerland, Europe, Africa, the Middle East, North America, Latin America, and the Asia Pacific. Givaudan SA was founded in 1796 and is headquartered in Vernier, Switzerland.

HOYA OTCMKTS:HOCPY

$127.04 +4.78 (+3.91%)

As of 05/23/2025 03:26 PM Eastern

HOYA Corporation, a med-tech company, provides high-tech and medical products worldwide. It operates through three segments: Life Care, Telecommunication, and Other. The company offers life care products, including eyeglass and contact lenses; medical endoscopes; intraocular lenses; laparoscopic surgical instruments; automatic endoscope cleaning equipment; and other medical related products, such as prosthetic ceramic fillers and metallic implants for orthopedics. It also operates Eyecity, a specialty retailer of contact lenses. In addition, the company provides information technology products, such as mask blanks and photomasks for manufacturing semiconductor chips; glass disks for hard disk drives; and imaging products that include optical glasses/optical lenses, colored glass filters, and laser equipment/UV light resources. Further, it engages in the research, development, manufacture, and sale of photomasks for manufacturing flat panel displays. Additionally, the company offers ReadSpeaker, a speech synthesis software; and cloud services comprising Kinnosuke, a time and attendance management service, as well as Yonosuke, an electronic payslip service. HOYA Corporation was founded in 1941 and is headquartered in Tokyo, Japan.

Recordati Industria Chimica e Farmaceutica OTCMKTS:RCDTF

$56.04 0.00 (0.00%)

As of 05/22/2025

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing's syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis. The company also develops CARBAGLU for hyperammonemia due to NAGS deficiency; QARZIBA, an apeiron for the treatment of high-risk neuroblastoma patients with a partial response at the chemotherapeutical through myeloablative therapy and stem cell transplantation, and relapsed or refractory neuroblastoma. In addition, it offers SYLVANT for the treatment of idiopathic multicentric Castleman diseases; REAGILA for Schizophrenia; and ELIGARD for hormone-dependent prostate cancer, as well as CAPHOSOL, a medical device for treatment of oral mucositis due to chemo and radiation therapy. The company was founded in 1926 and is headquartered in Milan, Italy. Recordati Industria Chimica e Farmaceutica S.p.A. operates as a subsidiary of Rossini S.à R.L.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time